DUBLIN--(BUSINESS WIRE)-- Research and Markets (http://www.researchandmarkets.com/research/smv8q8/ganaxolone) has announced the addition of GlobalData's new report "Ganaxolone (Epilepsy) - Forecast and Market Analysis to 2022" to their offering. PharmaPoint Drug Evaluation report, Ganaxolone (Epilepsy) - Forecast and Market Analysis to 2022. Epilepsy is a brain disorder characterized by spontaneously occurring and recurrent seizures. The market is heavily driven by the sales of antiepileptic drugs (AEDs) targeted at seizure reduction. The AED market is currently dominated by UCB's Keppra and GlaxoSmithKline's Lamictal. Although both drugs have experienced significant generic erosion, they form the mainstay of epilepsy treatment in the nine markets and will continue to have significant market share during the forecast period. Other key drugs include older generation AEDs such as Pfizer's Dilantin, Abbott's Depakote, and Novartis' Tegretol and Trileptal which still have significant usage due to their longevity in the market. However, the AED dominance landscape will continue to shift towards newer generation drugs particularly following the recent market entry of GlaxoSmithKline's Trobalt/Potiga and Eisai's Fycompa which both offer first-in-class mechanisms of action. Ganaxolone is a first-in-class synthetic neurosteroid analog of the endogenous neurosteroid allopregnanolone. It has novel GABA-A receptor modulation and unique broad-spectrum protective efficacy, and is under development for … Continue reading →

DUBLIN--(BUSINESS WIRE)-- Research and Markets (http://www.researchandmarkets.com/research/b9qggc/keppra_epilepsy) has announced the addition of GlobalData's new report "Keppra (Epilepsy) - Forecast and Market Analysis to 2022" to their offering. PharmaPoint Drug Evaluation report, Keppra (Epilepsy) - Forecast and Market Analysis to 2022. Epilepsy is a brain disorder characterized by spontaneously occurring and recurrent seizures. The market is heavily driven by the sales of antiepileptic drugs (AEDs) targeted at seizure reduction. The AED market is currently dominated by UCB's Keppra and GlaxoSmithKline's Lamictal. Although both drugs have experienced significant generic erosion, they form the mainstay of epilepsy treatment in the nine markets and will continue to have significant market share during the forecast period. Other key drugs include older generation AEDs such as Pfizer's Dilantin, Abbott's Depakote, and Novartis' Tegretol and Trileptal which still have significant usage due to their longevity in the market. However, the AED dominance landscape will continue to shift towards newer generation drugs particularly following the recent market entry of GlaxoSmithKline's Trobalt/Potiga and Eisai's Fycompa which both offer first-in-class mechanisms of action. Keppra (levetiracetam) is an approved first-in-class AED developed and marketed by UCB. The drug received FDA approval in November 1999, and EU approval in September 2000. Levetiracetam is … Continue reading →

DUBLIN--(BUSINESS WIRE)-- Research and Markets (http://www.researchandmarkets.com/research/v7xkm4/pharmapoint) has announced the addition of GlobalData's new report "PharmaPoint: Epilepsy - Germany Drug Forecast and Market Analysis to 2022" to their offering. GlobalData has released its new Country report, PharmaPoint: Epilepsy - Germany Drug Forecast and Market Analysis to 2022. Epilepsy is a brain disorder characterized by spontaneously occurring and recurrent seizures. The market is heavily driven by the sales of antiepileptic drugs (AEDs) targeted at seizure reduction. The AED market is currently dominated by UCB's Keppra and GlaxoSmithKline's Lamictal. Although both drugs have experienced significant generic erosion, they form the mainstay of epilepsy treatment in the nine markets and will continue to have significant market share during the forecast period. Other key drugs include older generation AEDs such as Pfizer's Dilantin, Abbott's Depakote, and Novartis' Tegretol and Trileptal which still have significant usage due to their longevity in the market. However, the AED dominance landscape will continue to shift towards newer generation drugs particularly following the recent market entry of GlaxoSmithKline's Trobalt/Potiga and Eisai's Fycompa which both offer first-in-class mechanisms of action. The main factor for the decline in this market is the launch of generics and the high rate of generic substitution … Continue reading →

DUBLIN--(BUSINESS WIRE)-- Research and Markets (http://www.researchandmarkets.com/research/48jdq7/brivaracetam) has announced the addition of GlobalData's new report "Brivaracetam (Epilepsy) - Forecast and Market Analysis to 2022" to their offering. PharmaPoint Drug Evaluation report, Brivaracetam (Epilepsy) - Forecast and Market Analysis to 2022. Epilepsy is a brain disorder characterized by spontaneously occurring and recurrent seizures. The market is heavily driven by the sales of antiepileptic drugs (AEDs) targeted at seizure reduction. The AED market is currently dominated by UCB's Keppra and GlaxoSmithKline's Lamictal. Although both drugs have experienced significant generic erosion, they form the mainstay of epilepsy treatment in the nine markets and will continue to have significant market share during the forecast period. Other key drugs include older generation AEDs such as Pfizer's Dilantin, Abbott's Depakote, and Novartis' Tegretol and Trileptal which still have significant usage due to their longevity in the market. However, the AED dominance landscape will continue to shift towards newer generation drugs particularly following the recent market entry of GlaxoSmithKline's Trobalt/Potiga and Eisai's Fycompa which both offer first-in-class mechanisms of action. Brivaracetam (BRV), which is an analog of the AED levetiracetam (Keppra), is being developed by UCB as an adjunctive therapy for the treatment of epilepsy, partial-onset seizures, and … Continue reading →

DUBLIN--(BUSINESS WIRE)-- Research and Markets (http://www.researchandmarkets.com/research/qssnjh/vx765_epilepsy) has announced the addition of GlobalData's new report "VX-765 (Epilepsy) - Forecast and Market Analysis to 2022" market research report to their offering. PharmaPoint Drug Evaluation report, VX-765 (Epilepsy) - Forecast and Market Analysis to 2022. Epilepsy is a brain disorder characterized by spontaneously occurring and recurrent seizures. The market is heavily driven by the sales of antiepileptic drugs (AEDs) targeted at seizure reduction. The AED market is currently dominated by UCB's Keppra and GlaxoSmithKline's Lamictal. Although both drugs have experienced significant generic erosion, they form the mainstay of epilepsy treatment in the nine markets and will continue to have significant market share during the forecast period. Other key drugs include older generation AEDs such as Pfizer's Dilantin, Abbott's Depakote, and Novartis' Tegretol and Trileptal which still have significant usage due to their longevity in the market. However, the AED dominance landscape will continue to shift towards newer generation drugs particularly following the recent market entry of GlaxoSmithKline's Trobalt/Potiga and Eisai's Fycompa which both offer first-in-class mechanisms of action. VX-765 is a first-in-class CASP1 inhibitor being developed by Vertex for the treatment of epilepsy. It represents a novel approach of using anti-inflammatory compounds for … Continue reading →

DUBLIN--(BUSINESS WIRE)-- Research and Markets (http://www.researchandmarkets.com/research/5qlwpl/lyrica_epilepsy) has announced a new report "Lyrica (Epilepsy) - Forecast and Market Analysis to 2022" to their offering. Epilepsy is a brain disorder characterized by spontaneously occurring and recurrent seizures. The market is heavily driven by the sales of antiepileptic drugs (AEDs) targeted at seizure reduction. The AED market is currently dominated by UCB's Keppra and GlaxoSmithKline's Lamictal. Although both drugs have experienced significant generic erosion, they form the mainstay of epilepsy treatment in the nine markets and will continue to have significant market share during the forecast period. Other key drugs include older generation AEDs such as Pfizer's Dilantin, Abbott's Depakote, and Novartis' Tegretol and Trileptal which still have significant usage due to their longevity in the market. However, the AED dominance landscape will continue to shift towards newer generation drugs particularly following the recent market entry of GlaxoSmithKline's Trobalt/Potiga and Eisai's Fycompa which both offer first-in-class mechanisms of action. Lyrica is a compound with both analgesic and anticonvulsant properties that was developed by Pfizer as a more potent successor to gabapentin (Neurontin). Pregabalin is the active pharmaceutical ingredient in Lyrica, and it binds with high affinity to the alpha2-delta site (an auxiliary subunit … Continue reading →

The one-day event features an exceptional collection of autism experts presenting the latest state-of-the-art methods of applied behavior analysis (ABA) for teaching perspective-taking and executive function skills to individuals with autism. San Diego, CA (PRWEB) March 08, 2013 The workshop, sponsored by the Center for Autism and Related Disorders (CARD), will be held at the Catamaran Resort and Spa from 9:00 am to 4:00 pm. It is designed for professionals, practitioners, family members, caregivers, and educators who work with children with autism. Attendees must register online at http://workshop.autismresearchgroup.org. The workshop will focus on the application of the state-of-the-art treatment of applied behavior analysis (ABA) for teaching advanced skills to children diagnosed with autism spectrum disorders. According to the Centers for Disease Control and Prevention (CDC), 1 in every 88 children in the U.S. is diagnosed with an autism spectrum disorder, making it more prevalent than juvenile diabetes, pediatric cancer, and childhood AIDS combined. We conducted a similar workshop in the Los Angeles area and received an overwhelming response. Whats exciting about this event is that we are dedicating a full day to cutting-edge training on how to teach advanced skills to individuals with autism, says workshop presenter Adel Najdowski, PhD, … Continue reading →

Illumina will work with SynapDxs to find a blood-test that could allow treatment to start earlier. Massachusetts startup SynapDx announced on Wednesday that it will work with DNA sequencer manufacturer Illumina to develop early detection tools for autism spectrum disorders, according to a release. SynapDx is trying to develop a blood-based test that will catch most cases of autism spectrum disorders in children earlier than current methods (see Can a Blood Test Detect Autism Early?). The advantage would be that treatments seem to work better the sooner they start. The challenge is that there arent clear biomarkers or genetic signals for the disorder, which is most likely a mix of many different conditions. But that doesnt seem to deter sequencing giant Illumina, which has been growing the diagnostic side of its business over the last few months (see A Brave New World of Prenatal DNA Sequencing). According to the release: SynapDx and Illumina share a vision of better pediatric care through the use of advanced molecular assays and sequencing technologies, said Stanley Lapidus, SynapDxs CEO. We look forward to broadly collaborating on multiple joint initiatives. SynapDx is currently recruiting participants into a clinical study of gene expression and autism in … Continue reading →